Literature DB >> 3531951

Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

H E Wander, D Meyer, P Schuff-Werner, G A Nagel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3531951     DOI： 10.1159/000216014

Source DB:  PubMed          Journal:  Onkologie        ISSN： 0378-584X


× No keyword cloud information.
  5 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.

Authors:  M M Buckley; H M Lamb
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 3.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

4.  A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

Authors:  N S Stuart; M H Cullen; T J Priestman; G R Blackledge; C J Tyrrell
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.

Authors:  K Kolarić; V Potrebica; D Vukas; Z Mechl; B Sopkova
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.